Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.
Blood. 2019 Mar 28;133(13):1436-1445. doi: 10.1182/blood-2018-11-835405. Epub 2019 Feb 6.
Interrogation of hematopoietic tissue at the clonal level has a rich history spanning over 50 years, and has provided critical insights into both normal and malignant hematopoiesis. Characterization of chromosomes identified some of the first genetic links to cancer with the discovery of chromosomal translocations in association with many hematological neoplasms. The unique accessibility of hematopoietic tissue and the ability to clonally expand hematopoietic progenitors in vitro has provided fundamental insights into the cellular hierarchy of normal hematopoiesis, as well as the functional impact of driver mutations in disease. Transplantation assays in murine models have enabled cellular assessment of the functional consequences of somatic mutations in vivo. Most recently, next-generation sequencing-based assays have shown great promise in allowing multi-"omic" characterization of single cells. Here, we review how clonal approaches have advanced our understanding of disease development, focusing on the acquisition of somatic mutations, clonal selection, driver mutation cooperation, and tumor evolution.
对造血组织进行克隆水平的研究已有 50 多年的历史,为正常和恶性造血提供了重要的见解。染色体的特征鉴定出了一些与癌症相关的最早的遗传联系,发现了与许多血液系统肿瘤相关的染色体易位。造血组织的独特可及性以及体外克隆扩增造血祖细胞的能力,为正常造血的细胞层次结构以及疾病中驱动突变的功能影响提供了重要的见解。在小鼠模型中的移植实验使我们能够在体内评估体细胞突变的功能后果。最近,基于下一代测序的检测方法在单细胞的多“组学”特征描述方面显示出巨大的潜力。在这里,我们回顾了克隆方法如何促进我们对疾病发展的理解,重点关注体细胞突变的获得、克隆选择、驱动突变合作和肿瘤进化。